Brokerages Set Charles River Laboratories International, Inc. (CRL) Target Price at $104.59

Charles River Laboratories International, Inc. (NYSE:CRL) has been given a consensus recommendation of “Buy” by the fourteen brokerages that are covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $104.59.

A number of research firms have recently weighed in on CRL. SunTrust Banks reissued a “buy” rating and set a $113.00 target price on shares of Charles River Laboratories International in a report on Friday, November 17th. Zacks Investment Research downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Monday, November 13th. Robert W. Baird set a $117.00 target price on Charles River Laboratories International and gave the stock a “buy” rating in a report on Monday, November 13th. ValuEngine downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Finally, Bank of America dropped their target price on Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, November 10th.

Shares of Charles River Laboratories International (NYSE CRL) traded up $0.09 during trading on Thursday, reaching $104.29. The company’s stock had a trading volume of 358,463 shares, compared to its average volume of 465,020. Charles River Laboratories International has a fifty-two week low of $69.51 and a fifty-two week high of $119.05. The firm has a market cap of $4,939.38, a P/E ratio of 20.49, a price-to-earnings-growth ratio of 1.66 and a beta of 0.89. The company has a quick ratio of 1.62, a current ratio of 1.88 and a debt-to-equity ratio of 1.13.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The company had revenue of $464.23 million during the quarter, compared to the consensus estimate of $458.93 million. During the same quarter last year, the firm earned $1.18 earnings per share. The company’s revenue was up 9.0% on a year-over-year basis. sell-side analysts expect that Charles River Laboratories International will post 5.13 EPS for the current year.

In other Charles River Laboratories International news, insider Davide Molho sold 6,165 shares of Charles River Laboratories International stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of Charles River Laboratories International stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $0.27, for a total value of $270,000.00. In the last ninety days, insiders purchased 10,500 shares of company stock valued at $2,885 and sold 1,012,147 shares valued at $1,591,514. 2.20% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. YorkBridge Wealth Partners LLC grew its position in Charles River Laboratories International by 445.5% in the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after acquiring an additional 891 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its position in Charles River Laboratories International by 69.0% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after acquiring an additional 548 shares during the last quarter. Advisor Group Inc. grew its position in Charles River Laboratories International by 159.4% in the third quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock valued at $165,000 after acquiring an additional 945 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after acquiring an additional 202 shares during the last quarter. Finally, Riverhead Capital Management LLC grew its position in Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after acquiring an additional 247 shares during the last quarter. Hedge funds and other institutional investors own 96.24% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2017/12/03/brokerages-set-charles-river-laboratories-international-inc-crl-target-price-at-104-59.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

What are top analysts saying about Charles River Laboratories International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Charles River Laboratories International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit